Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course hypofractionated radiotherapy plus adebrelimab and single-agent platinum as neoadjuvant therapy for locally advanced cervical cancer
ChiCTR2600125849Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in Cervical Cancer (CC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Pathological Complete Response Rate. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2600125849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125849.